文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

头孢克肟治疗淋病:越南河内耐药背景下的回顾性研究

Cefixime for the Treatment of Neisseria gonorrhoeae Infections in a Setting With Increased Antimicrobial Resistance: A Retrospective Study in Hanoi, Vietnam.
PubMed 文献 · Clin Infect Dis · 2026-01-01

在越南河内一项性健康项目中,回顾性比较头孢克肟800 mg与头孢曲松500 mg治疗的淋球菌感染。头孢克肟组随访培养均阴性,但核酸扩增检测(NAAT)阳性率高于头孢曲松组,且阳性均位于咽部,提示可能为咽部清除较慢或检测到非活菌。

要点

  • 头孢克肟组随访培养全部阴性,但NAAT阳性率高于头孢曲松组
  • NAAT阳性均位于咽部,可能反映咽部清除较慢或非活菌残留
  • 初始NAAT循环阈值较高与随访阳性几率降低相关

核心结论

  • 头孢克肟治疗者随访培养均阴性,但NAAT阳性率高于头孢曲松,咽部阳性可能为检测到非活菌。
  • NAAT咽部持续检出提示检测方法局限性,需结合培养判断疗效。

研究设计与样本

  • 回顾性研究,纳入2022年5月至2023年2月越南河内性健康项目中淋球菌感染者。
  • 头孢克肟800 mg组24例,头孢曲松500 mg组75例,治疗后10–21天进行治愈检测。
  • 多因素logistic回归分析治愈检测阳性的相关因素。

主要发现

  • 头孢克肟组NAAT阳性率45.0%,头孢曲松组17.7%(P = .014)。
  • 所有随访培养均阴性;NAAT阳性均位于咽部,其中1例同时直肠阳性。
  • 头孢克肟组随访检测中位时间12天(范围8–18天),头孢曲松组17天(范围8–28天)(P < .01)。
  • 初始NAAT循环阈值较高(aOR 0.81 [95%CI .70-.92])与头孢曲松治疗(aOR 0.11 [95%CI .02-.61])与随访阳性几率降低相关。

临床怎么用

  • 在耐药增加地区,头孢克肟治疗淋病后咽部NAAT可持续阳性,应结合培养判读。
  • 随访NAAT阳性不必然代表治疗失败,尤其咽部单一阳性时需谨慎解释。

局限性

  • 回顾性设计,样本量小(头孢克肟组24例)。
  • 两组随访检测时间存在差异(P < .01)。
  • NAAT无法区分活菌与非活菌,咽部阳性解释受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance in Neisseria gonorrhoeae is a global health problem. Ceftriaxone is the first-line treatment, while cefixime is recommended as an alternative. Data on cefixime treatment outcomes, particularly from areas with increased resistance, are limited. METHODS: We conducted a retrospective review of all gonococcal infections treated with cefixime 800 mg and ceftriaxone 500 mg within a sexual health program in Hanoi, Vietnam, between May 2022 and February 2023. Gonococcal infections were detected via culture or N. gonorrhoeae nucleic acid amplification testing (NAAT) at pharyngeal, rectal, or urogenital sites. A test of cure (TOC) was done 10-21 days posttreatment. Multivariate logistic regression was used to evaluate factors associated with TOC positivity. RESULTS: There were 24 participants treated with cefixime and 75 participants treated with ceftriaxone. The median time to follow-up testing was 12 days (range, 8-18 days) for cefixime and 17 days (range, 8-28 days) for ceftriaxone (P < .01). All follow-up cultures were negative. NAAT positivity was higher for cefixime (45.0%) compared to ceftriaxone (17.7%) (P = .014); all were positive at the pharynx, and 1 was also positive rectally. In multivariate analysis, higher initial NAAT cycle threshold values (adjusted odds ratio [aOR], 0.81 [95% confidence interval {CI}, .70-.92]) and ceftriaxone treatment (aOR, 0.11 [95% CI, .02-.61]) were associated with lower odds of positivity at TOC. CONCLUSIONS: Among N. gonorrhoeae infections treated with oral cefixime, we found no positive cultures at follow-up. Higher NAAT positivity among those treated with cefixime could reflect slower clearance at pharyngeal sites. However, persistent detection by NAATs at pharyngeal sites suggests the presence of nonviable bacteria, a limitation of the tests.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Adamson PC, David HM, Pham LQ, et al. Cefixime for the Treatment of Neisseria gonorrhoeae Infections in a Setting With Increased Antimicrobial Resistance: A Retrospective Study in Hanoi, Vietnam. Clin Infect Dis. 2026. PMID: 41504568. doi:10.1093/cid/ciaf607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。